Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02455193 · ClinicalTrials.gov registry record · NA

Neuronal Effects of Exercise in Schizophrenia

A NA study of Schizophrenia, sponsored by University of Colorado, Denver.

Recruiting
Registry status
NA
Development phase
140
Enrollment target
1
Study location

NCT02455193: Recruiting NA study of Schizophrenia, sponsored by University of Colorado, Denver.

NCT02455193 is a NA study of Schizophrenia that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 140 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02455193, a NA study of Schizophrenia, is actively recruiting participants, sponsored by University of Colorado, Denver.

RECRUITING
Registry status
NA
Development phase
140 participants
Enrollment target
1
Study location

Study Summary

This study plans to learn more about how common drugs prescribed to individuals with schizophrenia contribute to weight gain, as well as how exercise and diet impact appetite and the brain's response to food. In this study, the investigators will be evaluating how participants' brains respond to food images as well as asking questions about their food preferences and intake and clinical symptoms. The investigators may also ask participants to complete an exercise or diet intervention to see how this changes brain responses or food preferences.

Primary Outcome

Neuronal response (insula) while viewing visual food cues

Conditions Studied

Interventions

  • BEHAVIORAL Exercise
  • BEHAVIORAL Diet

Study Locations (1)

Colorado

  • University of Colorado Anschutz Medical Campus - Aurora

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2014-08
Est. Completion 2025-09
Phase NA
University of Colorado, Denver

1,283 total trials

What NCT02455193 shows while recruiting

NCT02455193 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (36% lower).

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Exercise is the first listed.

NCT02455193 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT02455193 about?

NCT02455193 is a clinical study titled "Neuronal Effects of Exercise in Schizophrenia". This study plans to learn more about how common drugs prescribed to individuals with schizophrenia contribute to weight gain, as well as how exercise and diet impact appetite and the brain's response to food. In this study, the investigators will be evaluating how participants' brains respond to foo...

What is the current status of trial NCT02455193?

This trial is currently recruiting. It is a NA study. The enrollment target is 140 participants. The study started on 2014-08. Estimated completion is 2025-09.

What conditions does trial NCT02455193 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT02455193?

The interventions under investigation include: Exercise (BEHAVIORAL), Diet (BEHAVIORAL).

Who is sponsoring clinical trial NCT02455193?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02455193 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02455193's enrollment target sits among peer trials

140 111th of 315 higher than 203 of 315 other Schizophrenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01419561 · 140 participants · Phase 2

    Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

  • NCT01624805 · 140 participants · Phase 2

    Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

  • NCT02369770 · 140 participants · NA

    Sensory-Motor Rehabilitation Post Stroke

  • NCT02507141 · 140 participants

    Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02455193, the US trial registry maintained by the National Library of Medicine. NCT02455193 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.